Thereafter, the mean changes in the 200- and 300-mg groups decreased, and the mean changes at week 12 of the treatment period were similar at all doses of canagliflozin.
After 26 weeks, HbA1c was reduced by 1.0% in the liraglutide 1.2 mg/metformin, the liraglutide 1.8 mg/metformin, and the glimepiride/metformin groups; decreased by 0.7% in the liraglutide 0.6 mg/metformin group; and increased by 0.1% in the placebo/metformin group.
Kidney Hg concentrations in the 4 mg/m group decreased after PND 21 and were not significantly different from controls and other treatment groups at PND45 and PND90.
Lumbar spine BMD increased by 2.8%and5.0%0% in the 1 mg and 2 mg groups, respectively and decreased by 0.04% in the placebo group.
The 1 mg group exhibited significantly decreased SL (p ≤ 0.012) compared with placebo, but was not significant on any other efficacy endpoint.
Mean fasting plasma glucose rose by 0.98 mmol/L (17.8 mg/dL) and 0.13 mmol/L (2.34 mg/dL) from baseline in the placebo group and dapagliflozin 10 mg group, respectively, but decreased by 0.53 mmol/L (9.54 mg/dL) in the dapagliflozin 20 mg group.
After treatment for 12 weeks the mean total of AV lesion decreased in both groups, i.e., control group decreased to 84.8 ± 47.83, whereas 160-mgs-isoflavone group decreased to 34.0 ± 24.82.
The median cell length of the negative control group and the 10 mg/L ferulic acid treatment group decreased compared with that of the control group, but at higher concentrations of ferulic acid, cell morphology was restored to normal and the median length was longer than that of the control group.
It should also be noted that the body weights of rats in the 516 mg/l group decreased more than 10% relative to controls, and that water intake significantly decreased ≥15% at the two highest doses (172 and 516 mg/l).
Thus, in patients with a baseline HbA1c ≥8.4%, decreases were 1.37 and 1.40% in the fasiglifam 25 and 50 mg groups, respectively, compared with decreases of 0.41 and 0.62% in those with a baseline HbA1c <8.4%.
